Welcome to our dedicated page for Icu Medical news (Ticker: ICUI), a resource for investors and traders seeking the latest updates and insights on Icu Medical stock.
ICU Medical, Inc. (Nasdaq: ICUI) is a medical technology company that publicly reports on its performance and activities through regular news releases and investor communications. The company describes itself as a global leader in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings, and it is headquartered in San Clemente, California.
The ICUI news feed on Stock Titan aggregates company announcements that cover a range of topics important to investors and industry observers. These include quarterly earnings results, updates to fiscal year guidance, and details on product line revenues across Consumables, Infusion Systems and Vital Care. ICU Medical’s earnings releases also discuss items such as gross profit, operating expenses, non-GAAP measures like adjusted EBITDA and adjusted diluted earnings per share, and commentary from management on recent performance.
In addition to financial results, ICU Medical issues news about corporate and strategic developments. Recent disclosures include the completion of Otsuka ICU Medical LLC, a joint venture with Otsuka Pharmaceutical Factory, Inc. focused on IV solutions manufacturing and innovation in North America. The company also announces its participation in major healthcare and investor conferences, such as the J.P. Morgan Healthcare Conference and events hosted by Piper Sandler, Wells Fargo and Morgan Stanley.
Through these updates, readers can follow how ICU Medical communicates its business progress, financial outlook and strategic initiatives. The ICUI news page on Stock Titan provides a centralized view of press releases related to earnings, guidance, joint ventures, conference appearances and other material events referenced in the company’s SEC filings. Investors and researchers can use this stream of information to monitor developments in ICU Medical’s infusion systems, consumables, vital care product lines and broader corporate activities over time.
ICU Medical, Inc. (Nasdaq:ICUI) announced the timing of its second quarter 2022 earnings release and conference call. The earnings results will be disclosed on August 8, 2022, at approximately 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET. Stakeholders can access the call at (877) 300-8521, using conference ID 10169518. A webcast will also be available on the company's website. ICU Medical specializes in infusion systems and critical care products, catering to hospital and home care settings.
ICU Medical reported strong financial results for Q1 2022, with revenue reaching $543.1 million, up $225.1 million from $318.0 million in Q1 2021. GAAP gross profit stood at $168.8 million (31% gross margin) compared to $112.7 million (35% margin) the previous year. However, the company faced a GAAP net loss of $(38.1) million or $(1.61) per share, contrasting with net income of $23.7 million in Q1 2021. Adjusted diluted EPS improved to $1.82, while adjusted EBITDA rose to $84.9 million.
ICU Medical, Inc. (Nasdaq: ICUI) has scheduled its first quarter 2022 earnings release for May 9, 2022, at 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET. The call will be accessible by phone at (877) 407-3982 and will also be streamed live via the company's website. ICU Medical specializes in infusion systems and critical care products used in various healthcare settings. The company emphasizes its commitment to quality and innovation for clinical customers worldwide.
SAN CLEMENTE, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- ICU Medical, a leader in innovative medical products, will participate in a virtual fireside chat at the KeyBanc Life Sciences & MedTech Investor Forum on March 22, 2022, at 8:15 a.m. PT (11:15 a.m. ET). The chat will be webcast live on the company's website and will include one-on-one meetings with investors on the same day. ICU Medical is recognized for its infusion systems and critical care products used globally in various healthcare settings.
ICU Medical, a leader in innovative medical products, announced its participation in a fireside chat at the Raymond James 43rd Annual Institutional Investors Conference. This event is scheduled for March 8, 2022, at 11:15 a.m. PT (2:15 p.m. ET). ICU Medical focuses on infusion systems and critical care products, serving hospitals and home care settings globally. The company aims to provide quality and innovation to its clinical customers. For more details, visit icumed.com.
ICU Medical, Inc. (Nasdaq:ICUI) reported fourth quarter 2021 revenue of $340.5 million, up from $320.5 million the previous year. GAAP gross profit rose to $127.5 million with a stable gross margin of 37%. The company posted a GAAP net income of $19.9 million ($0.91 per diluted share), down from $26.1 million ($1.21 per diluted share) year-over-year. Adjusted diluted EPS improved to $1.82 from $1.77. Looking ahead, ICU Medical expects adjusted EBITDA for fiscal 2022 between $450 million and $500 million, with adjusted diluted EPS ranging from $9.00 to $10.50.
ICU Medical (Nasdaq:ICUI) announced the schedule for its fourth quarter 2021 earnings release and conference call. The company will publish its results on February 24, 2022, at approximately 4:00 p.m. ET. A conference call will follow at 4:30 p.m. ET, accessible at (855) 327-6837 with conference ID 10017891. The call will also be available via webcast on the company's website. ICU Medical specializes in infusion systems and critical care products and is headquartered in San Clemente, California.
ICU Medical (NASDAQ: ICUI) has successfully acquired Smiths Medical from Smiths Group (LSE: SMIN.L), enhancing its position in the infusion therapy market. The combined revenue is projected at approximately $2.5 billion. This acquisition aims to create a scalable US-based competitor, improving supply chain stability and allowing for growth aligned with evolving clinical care models. ICU Medical plans to announce its complete FY 2022 guidance during its Q4 earnings call in late February.
ICU Medical (Nasdaq: ICUI) will present at the J.P. Morgan 40th Annual Healthcare Conference, scheduled from January 10-13, 2022. The presentation is set for January 12, 2022, at 10:30 a.m. PST (1:30 p.m. EST). Investors can access the live webcast on the company's website under the Investors tab. ICU Medical focuses on innovative products for infusion therapy and critical care, including IV smart pumps and closed system transfer devices. More details are available at www.icumed.com.
ICU Medical (Nasdaq:ICUI) reported a revenue increase of $336.1 million for the third quarter of 2021, up from $318.6 million in Q3 2020. The GAAP net income rose to $31.1 million, or $1.43 per diluted share, compared to $25.0 million, or $1.16 per diluted share, in the same quarter last year. Adjusted diluted EPS also increased to $2.07 from $1.90. The GAAP gross profit was $127.8 million with a gross margin of 38%. Notably, infusion consumables saw a significant increase, while IV solutions experienced a decline.